Proton Pump Inhibitors Approved in Pregnancy
All proton pump inhibitors except omeprazole are considered safe for use during pregnancy, with lansoprazole, pantoprazole, esomeprazole, and rabeprazole classified as FDA category B drugs, while omeprazole is category C and should be avoided when alternatives are available 1, 2.
Guideline-Based Recommendations
The 2024 BJOG Green-top Guideline explicitly states that women should be offered treatment with proton pump inhibitors for gastro-oesophageal reflux during pregnancy, noting that PPIs are "safe in pregnancy" 3. This represents the most current guideline-level evidence supporting PPI use.
Specific PPI Safety Profile
FDA Category B PPIs (Preferred):
- Lansoprazole - Safe for pregnancy use 1, 2
- Pantoprazole - Safe for pregnancy use 1, 2
- Esomeprazole - Safe for pregnancy use 2
- Rabeprazole - Safe for pregnancy use 2
FDA Category C PPI (Use with Caution):
Clinical Algorithm for PPI Use in Pregnancy
Step 1: Start with lifestyle modifications and dietary changes
Step 2: If symptoms persist, use calcium-containing antacids or alginates as first-line pharmacological treatment 1
Step 3: If inadequate response, add sucralfate 1
Step 4: If still symptomatic, use H2-receptor antagonists (ranitidine preferred) 4
Step 5: Reserve PPIs for intractable symptoms or complicated GERD - choose any category B PPI (lansoprazole, pantoprazole, esomeprazole, or rabeprazole), avoiding omeprazole 1, 2
Important Caveats
While the 2024 guideline supports PPI safety 3, a 2025 pharmacovigilance study detected potential adverse event signals with omeprazole specifically, including postpartum hemorrhage (ROR: 3.14), fetal growth restriction (ROR: 2.14), and pre-eclampsia (ROR: 1.95) 5. This reinforces avoiding omeprazole when category B alternatives exist.
The largest prospective controlled study (295 pregnancies) found no increased major congenital anomaly rates with PPIs overall (3.6% vs 3.8% controls) 6, supporting their use when clinically indicated after first trimester.
PPIs should only be used after the first trimester when possible 4, though the guideline evidence suggests they can be used when benefits outweigh risks throughout pregnancy for severe symptoms 3.